Scientific Advisory Board

CrownBio is not an ordinary CRO. Our founders have always been interested in drug discovery and how genomic and proteomic technologies could impact the drug discovery process. Our investors recognized early, developing these resources, committing to capacity, and maximizing global infrastructure would result in cost effective solutions and significant time savings for less innovative but FDA required experimental studies. With over a decade of experience in their former large pharma tenures, our scientific team, is always pushing their own pharmacological interests and want to see them rapidly applied to drug discovery. Thus, the only missing piece was the in-depth knowledge of scientists who have spent their entire careers devoted to cancer drug discovery, exploited mechanisms of drug resistance ,driven over 25 investigational drugs to clinical trials, and successfully had 6 drugs approved for the treatment of cancer by worldwide regulatory agencies. So ask yourself, why wouldn’t CrownBio have a have a high-powered, dedicated advisory board?

• Homer Pierce, PhD (chair) - Ex VP oncology, Eli Lilly & Co.
• Melanie Cobb, PhD - Dean, UT South Western
• Sarah Courtniedge, PhD - Professor, Burnham Institute / Ex CSO, Sugen
• Steve Kaldor